PTEN is a tumor suppressor that is one of the most frequently mutated genes in human cancer, and the pan-AKT kinase inhibitor capivasertib in combination with the selective estrogen receptor degrader (SERD) fulvestrant is FDA-approved for the treatment of patients with PTEN-mutant HR+/HER2- metastatic breast cancer [32]. The gene discussed is HR; the disease is neoplasm.